2023 World Conference on Lung Cancer (Posters)-EP12.01. First-line Aumolertinib Treatment in Non-Small Cell Lung Cancer (NSCLC) with Primary EGFR T790M Mutation: A Report of two Cases

EP12.01. First-line Aumolertinib Treatment in Non-Small Cell Lung Cancer (NSCLC) with Primary EGFR T790M Mutation: A Report of two Cases - PDF(Slides)

Back to course

Pdf Summary

Two cases of non-small cell lung cancer (NSCLC) patients with primary EGFR T790M mutation were successfully treated using aumolertinib, according to a report by Li Zang from The second Hospital of Tianjin Medical University in China. Previous research has found that a small percentage of TKI-naive patients with EGFR activating mutations also have the primary T790M mutation. However, there are still no standard recommendations for the first-line treatment of NSCLC with primary EGFR T790M mutation, especially in patients with co-mutations of EGFR-sensitive mutation and primary T790M mutation. <br /><br />The first case presented a 64-year-old female with right upper lobe adenocarcinoma and bone metastases. The patient received aumolertinib treatment, and regular follow-up showed significant shrinkage of the tumor. The best response was partial response (PR), and the progression-free survival was 22 months. After tumor progression, the patient received chemotherapy as a second-line treatment. <br /><br />The second case presented a 61-year-old female with right upper lobe adenocarcinoma and bone metastases. The patient also received aumolertinib treatment, and regular follow-up showed significant tumor shrinkage. The best response was PR, and the progression-free survival was 24 months with no obvious adverse events.<br /><br />This report suggests that aumolertinib monotherapy can provide durable disease control and a satisfactory safety profile for NSCLC patients with primary T790M mutation. However, further investigations with larger samples are needed to confirm the efficacy of EGFR-TKI treatment for patients with primary T790M mutation.

Asset Subtitle

Li Zang

Meta Tag

Speaker Li Zang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

non-small cell lung cancer

NSCLC

EGFR T790M mutation

aumolertinib

Li Zang

The second Hospital of Tianjin Medical University

China

TKI-naive patients

EGFR activating mutations

first-line treatment